Sector Gamma AS purchased a new stake in shares of Eli Lilly And Co (NYSE:LLY) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 152,105 shares of the company’s stock, valued at approximately $17,010,000. Eli Lilly And Co comprises approximately 2.9% of Sector Gamma AS’s portfolio, making the stock its 12th biggest position.
Several other institutional investors and hedge funds have also modified their holdings of LLY. Capital Investment Advisory Services LLC raised its holdings in shares of Eli Lilly And Co by 3.4% during the 2nd quarter. Capital Investment Advisory Services LLC now owns 2,831 shares of the company’s stock valued at $304,000 after buying an additional 92 shares in the last quarter. Investors Research Corp increased its stake in Eli Lilly And Co by 5.6% in the 3rd quarter. Investors Research Corp now owns 1,764 shares of the company’s stock worth $197,000 after purchasing an additional 93 shares during the period. Global Wealth Management Investment Advisory Inc. increased its stake in Eli Lilly And Co by 10.2% in the 2nd quarter. Global Wealth Management Investment Advisory Inc. now owns 1,023 shares of the company’s stock worth $113,000 after purchasing an additional 95 shares during the period. FTB Advisors Inc. increased its stake in Eli Lilly And Co by 3.0% in the 3rd quarter. FTB Advisors Inc. now owns 3,275 shares of the company’s stock worth $366,000 after purchasing an additional 95 shares during the period. Finally, Lourd Capital LLC increased its stake in Eli Lilly And Co by 2.7% in the 2nd quarter. Lourd Capital LLC now owns 3,723 shares of the company’s stock worth $412,000 after purchasing an additional 97 shares during the period. Hedge funds and other institutional investors own 77.22% of the company’s stock.
Eli Lilly And Co stock traded up $0.76 during trading hours on Friday, reaching $113.53. The company had a trading volume of 2,190,598 shares, compared to its average volume of 7,683,282. The company has a debt-to-equity ratio of 4.09, a current ratio of 1.17 and a quick ratio of 0.88. The company has a 50-day moving average price of $110.61 and a 200 day moving average price of $112.67. The firm has a market cap of $106.81 billion, a price-to-earnings ratio of 20.46, a P/E/G ratio of 1.82 and a beta of 0.16. Eli Lilly And Co has a 12-month low of $101.36 and a 12-month high of $132.13.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.645 per share. The ex-dividend date is Thursday, November 14th. This represents a $2.58 annualized dividend and a dividend yield of 2.27%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.
In other news, SVP Alfonso G. Zulueta sold 4,500 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $117.00, for a total transaction of $526,500.00. Following the transaction, the senior vice president now directly owns 33,806 shares of the company’s stock, valued at $3,955,302. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Alfonso G. Zulueta sold 19,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $112.91, for a total value of $2,201,745.00. Following the transaction, the senior vice president now directly owns 38,306 shares in the company, valued at $4,325,130.46. The disclosure for this sale can be found here. Over the last three months, insiders have bought 8,405 shares of company stock worth $909,004 and have sold 614,373 shares worth $70,546,895. 0.11% of the stock is currently owned by insiders.
A number of equities analysts have commented on LLY shares. UBS Group decreased their price target on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating on the stock in a research note on Thursday, October 17th. Bank of America started coverage on Eli Lilly And Co in a research note on Wednesday, October 16th. They issued a “buy” rating and a $133.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $130.03.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: Fundamental Analysis
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.